The rescheduling of marijuana from Schedule I to Schedule III under a recent executive order from President Trump has renewed chatter about whether cannabis equities are finally due for a recovery. For companies like Tilray Brands - whose shares have shed more than 90% of their value over the past five years - the policy shift offers something. Just not nearly enough. The structural problems eating into cannabis company financials predate this administration, and rescheduling alone doesn't touch most of them.
What Rescheduling Actually Changes - and What It Doesn't
Schedule III status does carry real, if narrow, benefits. The most consequential one for licensed cannabis businesses is tax relief. Under 280E of the Internal Revenue Code, companies selling Schedule I or Schedule II controlled substances are barred from deducting ordinary business expenses - payroll, rent, marketing, utilities. Medical cannabis operators have been paying effective tax rates far above those of comparable retail or consumer goods businesses precisely because of this rule. Moving to Schedule III removes that penalty for FDA-approved and state-legal medical cannabis products, which lowers the operating cost floor in a meaningful way.
It also eases the path for formal research into cannabis's potential health applications, which could eventually expand the medical market. That's a slow-moving benefit, not a quarterly catalyst.
Here's the catch, though: rescheduling is not federal legalization. Cannabis remains a controlled substance. Interstate commerce in cannabis products is still prohibited, which means every multi-state operator - Tilray included - must maintain cultivation, processing, and distribution infrastructure in each state where it does business. That isn't an efficiency problem at the margins. It's a structural drag that makes the unit economics of scaling a cannabis business look nothing like scaling a consumer packaged goods company, a brewery, or even a pharmaceutical firm. The cost of vertical integration across state lines compounds with every new market entered.
The Interstate Commerce Wall Hasn't Moved
For dispensary operators and cannabis retailers watching this from the ground level, the interstate shipping ban is the single most persistent source of operational friction. Seed-to-sale tracking systems like METRC are designed around state-level compliance, which is appropriate given how licensing works - but also reflects just how fragmented this market remains. Wholesale menus, supplier relationships, product batch approvals, lab testing requirements, compliant packaging standards - all of it is replicated state by state, with meaningful variation in rules between jurisdictions.
A consumer packaged goods brand can manufacture in one facility, achieve cost efficiencies of scale, and distribute nationally. A cannabis brand cannot. The result is higher cost-of-goods, compressed margins, and - for many operators - chronic unprofitability. Rescheduling doesn't change the shipping ban. A congressional act or full federal legalization would need to do that.
There is a hearing scheduled to consider whether broader forms of cannabis - recreational included - should also be rescheduled or reclassified. That's a genuinely significant development to watch. But it is a proceeding, not an outcome. The distance between an administrative hearing and a rule change that actually reshapes interstate commerce is long, and the timeline is uncertain.
Tilray's Diversification Strategy: Sensible, but Not a Fix
Tilray's response to the cannabis market's chronic underperformance has been diversification - most visibly into craft brewing, where the company has grown through acquisition to become one of the larger players in that segment. It also maintains a footprint in CBD and hemp-based products in the U.S., categories that operate under a different regulatory framework and don't carry the same 280E exposure.
That's a defensible strategic posture. The problem is execution. Revenue growth has been inconsistent, and the company has not reached profitability. Diversification can reduce dependence on a single regulatory outcome, but it doesn't resolve the underlying question of whether any cannabis company - in the current environment - has built a durable competitive position that would survive a fully open federal market.
That last point matters more than it might appear. If federal legalization does arrive, the cannabis sector won't just become more accessible to existing players. It will become accessible to large consumer goods corporations, alcohol and tobacco companies, pharmaceutical manufacturers, and well-capitalized retail conglomerates. These are entities with established distribution infrastructure, national brand recognition, deep balance sheets, and extensive experience operating inside tightly regulated consumer categories. The competitive reset that full legalization would trigger could be harder on today's cannabis companies than the current restricted environment.
What B2B Operators Should Actually Take From This Moment
For licensed cannabis businesses - dispensary operators, cultivators, processors, and the software and compliance vendors serving them - the rescheduling news is worth tracking, but it doesn't change day-to-day operations in any immediate way. The practical implications are worth keeping clear:
- Medical cannabis companies may see reduced federal tax burden as Schedule III rules apply - but this requires legal and tax counsel to assess at the entity level, and the transition isn't automatic.
- Interstate commerce restrictions remain intact. Supply chain strategy, licensing in each state, and state-by-state compliance obligations don't change.
- Recreational cannabis is not covered by the current rescheduling decision. Operators in adult-use markets should not plan around imminent federal policy changes affecting that segment.
- Further rescheduling hearings are scheduled, which means the regulatory environment could continue to shift - incrementally and unpredictably.
The broader lesson from watching cannabis equity performance over the past several years isn't that the market lacks potential. It's that regulatory complexity, structural inefficiency, and the absence of federal clarity make even well-positioned companies hard to value with confidence. The 280E fix is real. The rest is still a waiting game - and the people running dispensaries and licensed operations already know that better than most.
